Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 251 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fed State Clear all

Conditions: Healthy Volunteers in Fed and Fasted State
Interventions: Dexmethylphenidate; Drug
Lead sponsor: Cingulate Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Human Gastrointestinal Physiology Data
Interventions: Single dose of ibuprofen (800 mg tablet), Pulmocare, two 8.0 oz (236.6 mL) cans; Drug · Dietary Supplement
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Healthy Subjects
Interventions: Fezolinetant; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cytochrome P450 Interaction
Interventions: Lu AF35700, Itraconazole (200 mg), Itraconazole (300 mg); Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Primary Sclerosing Cholangitis (PSC)
Interventions: CS0159; Drug
Lead sponsor: Cascade Pharmaceuticals, Inc; Other
Eligibility: 18 Years to 55 Years
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Gout
Interventions: RDEA3170 4.5 mg, RDEA3170 6 mg, RDEA3170 12 mg; Drug
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Volunteers
Interventions: LY2157299; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Energy Deficiency Due to Short-term Fasting
Interventions: r-metHuLeptin; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 30 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: CLL / SLL, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma), Marginal Zone Lymphoma(MZL), Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia
Interventions: Lonitoclax (ZE50-0134); Drug
Lead sponsor: Lomond Therapeutics Holdings, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Louisville, Kentucky • Chapel Hill, North Carolina • Cincinnati, Ohio + 2 more

Conditions: Advanced Solid Tumors
Interventions: Alisertib; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Prostatic Neoplasms, Genital Neoplasms, Male, Genital Diseases, Male, Prostatic Diseases
Interventions: EPI-506; Drug
Lead sponsor: ESSA Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Scottsdale, Arizona • Ann Arbor, Michigan • Detroit, Michigan + 1 more

Conditions: KRAS p.G12C Mutant Advanced Solid Tumors
Interventions: sotorasib, Anti PD-1/L1, Midazolam; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 713 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 39
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 29 more

Conditions: Heart Failure, Congestive
Interventions: GSK2798745 Micronized API without SLS and hypermellose (Tablet A), GSK2798745 Micronized API with SLS and hypermellose (Tablet B), GSK2798745 milled API without SLS and hypermellose (Tablet C); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Infections, Bacterial
Interventions: Gepotidacin RC Tablet, Gepotidacin HSWG Tablet, Gepotidacin Capsule; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Anaheim, California • Austin, Texas

Conditions: Healthy Participants
Interventions: Plixorafenib, Cobicistat; Drug
Lead sponsor: Fore Biotherapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Acute Promyelocytic Leukemia
Interventions: SY-2101, Arsenic Trioxide; Drug
Lead sponsor: Syros Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Birmingham, Alabama • Chicago, Illinois • Baltimore, Maryland + 5 more

Conditions: PKU
Interventions: Nonradioactive stable oral isotope, Test diet; Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pain
Interventions: MEB-1170, Placebo; Drug
Lead sponsor: Mebias Discovery, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy
Interventions: amlodipine 10 mg tablet; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Symptomatic Neurogenic Orthostatic Hypotension
Interventions: Droxidopa; Drug
Lead sponsor: Chelsea Therapeutics; Industry
Eligibility: 65 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Diabetes Mellitus
Interventions: saxagliptin, metformin XR, saxagliptin + metformin XR (FDC tablet); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Volunteers
Interventions: Centanafadine SR, Centanafadine QD XR; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy
Interventions: Miricorilant Treatment A, Miricorilant Treatment B, Miricorilant Treatment C, Miricorilant Treatment D; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: LY3410738, Esomeprazole; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Daytona Beach, Florida

Search by objective public record fields.

In-clinic Crossover Study in Subjects With Two Treatments (Fed vs Fasted)

Modernization of in vivo-in Vitro Oral Bioperformance Prediction and Assessment

A Study to Assess the Effect of Food With Fezolinetant in Healthy Female Participants

Study Evaluating the Effect of Multiple Doses of Itraconazole on the Drug Lu AF35700 in Healthy Young Men and Women

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159

RDEA3170 PK/PD Study

A Study of LY2157299 in Healthy Participants

Pharmacokinetics of Leptin Administration During Fasting

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

Study of MLN8237 in Participants With Advanced Solid Tumors

Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets

To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.

A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants.

A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia

PKU Protein Requirements

A Study to Assess the Safety of MEB-1170 in Healthy Subjects

Bioequivalence Study of Amlodipine 10mg Tablets Under Fed Conditions

Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)

A Trial to Compare the Amount of Centanafadine That Enters the Bloodstream for Two Different Formulations of Centanafadine

Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects

A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants